|
Fluoxetine for Anxious Children Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Fluoxetine for Anxious Children conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Fluoxetine for Anxious Children Clinical research trials and Fluoxetine for Anxious Children health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Fluoxetine for Anxious Children. Fluoxetine for Anxious Children Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Fluoxetine for Anxious Children clinical trial. Human subjects frequently get the finest healthcare available for their Fluoxetine for Anxious Children condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Fluoxetine for Anxious Children  Fluoxetine for Anxious Children
Fluoxetine for Anxious Children
For Condition: Anxiety Disorders
Status: No longer recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to see if it is safe and effective to use fluoxetine to treat children and adolescents with Generalized Anxiety Disorder (GAD). Anxiety disorders are one of the most common psychiatric disorders in children and adolescents, and can cause disturbances in the child's school, social, and family lives. Having an anxiety disorder puts a child at risk for depression and drug abuse, and appears to continue into adulthood. There is very little information on anxiety medications for children. Children will be assigned randomly (like tossing a coin) to receive either fluoxetine or an inactive placebo for 12 weeks. Each child will be monitored for symptoms and side effects throughout the study. He/she will have blood tests at Weeks 4, 8, and 12 to measure drug levels in the blood. The study will last for 12 weeks. A child is eligible for this study if he/she: Is 8 to 17 years old and has anxiety disorder. A child will not be eligible for this study if he/she: Has current major depression, panic disorder, or obsessive-compulsive disorder, or abuses alcohol or drugs.
Details: To evaluate the safety and efficacy of fluoxetine as a treatment for children and adolescents with Generalized Anxiety Disorder (GAD). Anxiety disorders are among the most common childhood and adolescent psychiatric disorders and are often associated with academic, social, and family morbidity. These disorders frequently increase the risk for developing other psychiatric disorders (e.g., depression, substance abuse), aggregate in families, and appear to continue into adulthood. Except for Obsessive-Compulsive Disorder, there are very few pharmacological treatment studies for childhood anxiety disorders. Given the sparsity and methodological problems of previous anxiety pharmacological studies, it is clear that further investigation of the use of pharmacological treatment of children and adolescents with these disorders is needed. Patients are randomized to receive either fixed-dose fluoxetine or placebo for 12 weeks. Patients are assessed for psychiatric symptomatology, functional status, and side effects. In addition, to assess attainment of steady state and compliance with treatment, plasma levels of fluoxetine and norfluoxetine are measured at 4, 8, and 12 weeks. To standardize the treatment protocol and to assure that both groups (fluoxetine and placebo) receive equivalent nonpharmacological treatment, a manual is used. Potential predictors of clinical response (such as age, sex, duration and severity of anxiety, school absenteeism, sub-syndromal depressive symptoms, family history of anxiety or mood disorders) are explored.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind
Minimum Age/Maximum Age: 8 Years/17 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: Patients must have: Generalized anxiety disorder. Exclusion Criteria: Excluded: Patients with current major depression, as well as patients with panic and obsessive-compulsive disorder. Excluded: Current substance abuse.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BorisBirmaher, Principal Investigator,
Additional Information:
Study ID Numbers: MH53681;
Study Start Date: June 1997
Record last reviewed: June 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000381
Other Anxiety Disorders Studies:
1. Child and Adolescent Anxiety Disorders (CAMS)
2. Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning
3. Treatment for Anxiety in Children
4. The Psychobiology of Childhood Temperament
5. Fluoxetine for Anxious Children
Related Studies:
Other Anxiety Disorders Clinical Trials
Other Clinical Trials
Other Clinical Trials
Fluoxetine for Anxious Children
|
|
|
|
|
|
|
|
